drugset / Trial / NCT03588598
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
Timeline
- Start
- 2018-09-07
- Primary completion
- 2019-07
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHC014748M | Unknown | 50 mg | Oral |
| Subject | SHC014748M | Unknown | 100 mg | Oral |
| Subject | SHC014748M | Unknown | 150 mg | Oral |
| Subject | SHC014748M | Unknown | 200 mg | Oral |
| Subject | SHC014748M | Unknown | 250 mg | Oral |